logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin usTools
 

Tumour Angiogenesis

Introduction

Angiogenesis, or formation of new blood vessels from other pre-existing vessels, is essential for the tumour growth, progression and the subsequent appearance of metastases in other organs. For all these reasons, in recent years, the anti-angiogenic therapies have been a point of intense research in developing new cancer treatments. More than 50 pharmacological inhibitors of angiogenesis are currently at different points of its clinical development. Most of the targets for these compounds are different factors that induce angiogenesis. One of the most important is the specific vascular endothelial growth factor (VEGF), which stimulates the proliferation and migration of endothelial cells and the formation of new blood vessels. In fact, the first selective inhibitor of angiogenesis that has been approved for use in patients is bevacizumab (Avastin), a neutralizing antibody against VEGF. Other angiogenic factors such as TGF-beta or angiopoietins not induce proliferation of the endothelium but its stabilization.

 

Key points of interest in this field are the identification of new molecular targets of the angiogenic cascade, as well as the determination of the specific effect of anti-angiogenic molecules in different tumour models. On the other hand, it has shown that anti-angiogenic therapies are most effective when they are administered in combination with chemotherapy or radiotherapy. It is therefore important to know what combinations, regimens and administration dosage are the most effective, as well as to identify biomarkers that can help assess the effectiveness of anti-angiogenic treatments.

 

Finally, despite being more difficult than the endothelial cells develop drug resistance due to its high genetic stability, after some time of treatment is just creating resistance to the anti-angiogenic therapies. Understanding the mechanisms involved in this resistance will help to prevent them or seek alternative therapies.

 

In order to answer some of these questions, our group of tumour angiogenesis from IDIBELL tries to make the environmental research that we have in our institution, combining the knowledge of researchers with the basic training to clinical, leading research projects and promoting the generation of new joint projects.

 

The group consists of five research lines or independent subgroups, each leaded by a researcher:

 

. Subgroup Angiogenic Factors. PI: Francisco Viñals

. Subgroup Resistance to Anti-angiogenic therapies and malignant cancer. IP: Oriol Casanovas
 
. Subgroup "Metronomic Administration of chemotherapeutic agents as anti-angiogenic therapy. PI: Berta Laquente

 

. Subgroup "Research of noninvasive biomarkers in clinical trials with anti-angiogenic. PI: Margarita García

. Subgroup Signaling pathways in angiogenesis. PI: Mariona Graupera




Research lines

Mechanisms involved in the proangiogenic effect of TGFbeta, EGF and VEGF

Metronomic administration of chemotherapeutic agents as antiangiogenic therapy

Investigation of noninvasive biomarkers in clinical trials with antiangiogenic

Radiation-induced angiogenesis: cytoprotective response

Mechanisms of resistance and invasion in response to antiangiogenic therapies in animal models and in human tumors

Signaling pathways in angiogenesis.


Selected papers (2013)

 

Soler A., Serra H., Pearce W.,Angulo A., Guillermet-Guibert J.,  Friedman L. S., Vinals F., Gerhardt H., Casanovas O., Graupera M., Vanhaesebroeck B.

Inhibition of the p110 alpha isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis          

Journal of Experimental Medicine. 2013 Sep 23;210(10):1937-45.

 

 

Moserle, L.; Casanovas, O.        

Anti-angiogenesis and metastasis: a tumour and stromal cell alliance   

Journal of Internal Medicine 2013 Feb;273(2):128-37

 

Graupera M.,Potente M.

Regulation of angiogenesis by PI3K signaling networks               

Experimental Cell Research. 2013 May 15;319(9):1348-55.

 

Juliachs, M.; Castillo-Avila, W.; Vidal, A.; Piulats, J. M.; Garcia del Muro, X.; Condom, E.; Hernandez-Losa, J.; Teixido, C.; Pandiella, A.; Graupera, M.; Casanovas, O.; Germa, J. R.; Villanueva, A.; Vinals, F.

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor               

International Journal of Cancer. 2013 Jul;133(1):235-46.

 

Juliachs M.,Vidal A., Garcia del Muro X.,  Piulats J.M., Condom E., Casanovas O., Graupera M.,Germa J.R., Villanueva A., Vinals F.

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors               

BMC Cancer 2013 Aug 10;13:382. 

 

Vives M, Ginestà MM, Gracova K, Graupera M, Casanovas O, Capellà G, Serrano T, Laquente B & Viñals F

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.      

International Journal of Cancer. 2013 Nov 15;133(10):2464-72. 

imatge personal
 

Group leader

Oriol Casanovas
Telephone  
+34 932607344
E-mail  
ocasanovas@idibell.cat
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell